^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Jubbonti (denosumab-bddz) (RANK ligand inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sandoz receives FDA approval for first and only denosumab biosimilars
Published date:
05/03/2024
Excerpt:
Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines...in patients with multiple myeloma...
